BofA Securities analyst Alec W. Stranahan reiterated a Buy rating and $47.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments

TD Cowen on Prime Medicine (PRME): 'We continue to view PRME as undervalued for the platform’s potential'July 8, 2026 12:30 PM